Clinical Trials Sponsored by ECRI bv

Total 548 results

Fundacja Ośrodek Badań Medycznych
KCRI

Withdrawn

Effect of the Repeated Loading Dose of Clopidogrel and High Dose of Clopidogrel Continuous Therapy on the Platelet Aggregation Inhibition in Patients With Myocardial Infarction Undergoing Interventional Treatment. (REL-0609)

Acute Myocardial Infarction

Poland
SCRI Development Innovations, LLC
Bayer

Completed

Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients

Multiple Myeloma

United States
SCRI Development Innovations, LLC
Novartis

Withdrawn

A Study of Panobinostat (LBH589) as Second-Line Therapy in Patients With Chronic Graft-Versus-Host Disease

Chronic Graft-Versus-Host Disease

United States
SCRI Development Innovations, LLC
Bayer

Completed

Study of the Pharmacokinetics/Safety of Sorafenib + Capecitabine in Advanced Solid Tumors

Refractory Malignancy

United States
Seattle Children's Research Institute (SCRI)

Completed

Malaria Challenge in Healthy Volunteers (ITV)

Malaria

United States
SCRI Development Innovations, LLC
Biogen

Completed

Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma

Non-Hodgkins Lymphoma

United States
SCRI Development Innovations, LLC
GlaxoSmithKline

Completed

Weekly Topotecan in Patients Treated for Metastatic Colorectal Cancer

Colon Cancer

United States
SCRI Development Innovations, LLC
Novartis

Completed

PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced Malignancies

Advanced Malignancies | Refractory Malignancy

United States
Morphotek
SCRI Development Innovations, LLC

Completed

Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC

Adenocarcinoma | Breast Cancer | Carcinoma, Non-Small-Cell Lung | Colorectal Cancer | Pancreatic Cancer

United States
SCRI Development Innovations, LLC
Celgene

Terminated

Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma

Transitional Cell Carcinoma | Bladder Cancer | Urothelial Carcinoma

United States
SCRI Development Innovations, LLC
Novartis

Completed

INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme

Renal Cell Carcinoma | Colorectal Cancer | Glioblastoma Multiforme | Gliosarcoma

United States
SCRI Development Innovations, LLC
Pfizer

Completed

Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer

Small Cell Lung Cancer

United States
Medicure
SCRI Development Innovations, LLC

Completed

Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention (SAVI-PCI)

Myocardial Infarction | Unstable Angina | Acute Coronary Syndromes

United States
SCRI Development Innovations, LLC
Novartis

Completed

Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme

Glioblastoma Multiforme

United States
Seattle Children's Research Institute (SCRI)

Terminated

Phase 1/2a Trial of Pf GAP p52-/p36- Sporozoite Malaria Vaccine

Malaria

United States
Medicure
SCRI Development Innovations, LLC

Withdrawn

Aggrastat Truncated Length Against Standard Therapies in Percutaneous Coronary Intervention (ATLAST-PCI)

Myocardial Infarction | Percutaneous Coronary Intervention | Unstable Angina | Acute Coronary Syndromes
SCRI Development Innovations, LLC
Novartis

Terminated

Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States
SCRI Development Innovations, LLC
Novartis

Completed

Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor

Gastrointestinal Stromal Tumor

United States
SCRI Development Innovations, LLC
GlaxoSmithKline

Completed

Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
SCRI Development Innovations, LLC
Bayer

Completed

Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib for Glioblastoma Multiforme

Glioblastoma Multiforme

United States
SCRI Development Innovations, LLC
Amgen

Completed

Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type NSCLC

Non-Small-Cell Lung Cancer

United States
SCRI Development Innovations, LLC
Novartis

Completed

LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients

Breast Cancer

United States
SCRI Development Innovations, LLC
Novartis

Completed

Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer

Metastatic Breast Cancer

United States
SCRI Development Innovations, LLC
Bayer

Completed

Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer

Breast Cancer

United States
SCRI Development Innovations, LLC
GlaxoSmithKline

Completed

Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer

Carcinoma, Small Cell

United States
SCRI Development Innovations, LLC
GlaxoSmithKline

Completed

Topotecan Plus Paclitaxel and Carboplatin in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Carcinoma

Ovary Cancer
Medical University of Warsaw
KCRI

Unknown

Restenosis Treatment With Rapamycin Eluting Stent or Paclitaxel Eluting Balloon Catheter (RESTENOZA) (ISRII)

In-Stent Restenosis

Poland
SCRI Development Innovations, LLC
GlaxoSmithKline

Completed

Weekly Topotecan in the Second-Line Treatment of Small Cell Lung Cancer

Lung Cancer
Thubrikar Aortic Valve, Inc.
KCRI

Recruiting

Safety and Performance Study of the Optimum Transcatheter Aortic Valve

Severe Aortic Stenosis

Poland
SCRI Development Innovations, LLC
Amgen

Completed

Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers

Neuroendocrine Cancer

United States
Xtrac O.S.
KCRI; Scopus Research

Active, not recruiting

Safety and Preliminary Performance of Xtrac O.S. System for Lead Extraction. (XTR)

Bradycardia

Israel
SCRI Development Innovations, LLC
Celgene

Completed

Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer

Metastatic Breast Cancer

United States
SCRI Development Innovations, LLC
Bayer

Completed

Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

United States
SCRI Development Innovations, LLC
Novartis

Completed

LBH589 Treatment for Refractory Clear Cell Renal Carcinoma

Renal Cell Carcinoma

United States
SCRI Development Innovations, LLC
Sanofi

Completed

Trastuzumab and Oxaliplatin in Patients With Metastatic Breast Cancer

Breast Cancer

United States
SCRI Development Innovations, LLC
Pfizer

Completed

A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)

Colorectal Cancer

United States
SCRI Development Innovations, LLC
Novartis

Completed

Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib

Non Small Cell Lung Cancer

United States
SCRI Development Innovations, LLC
Novartis

Withdrawn

Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel

Advanced Prostate Cancer

United States
SCRI Development Innovations, LLC
Amgen

Completed

FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only

Colorectal Cancer

United States
SCRI Development Innovations, LLC
Novartis

Completed

Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors

Malignant Solid Tumour

United States
SCRI Development Innovations, LLC
Bayer

Completed

Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer

Ovarian Cancer

United States
SCRI Development Innovations, LLC
Bayer

Completed

PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors

Refractory Solid Tumors

United States
SCRI Development Innovations, LLC
Novartis

Completed

Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma

Metastatic Melanoma

United States
SCRI Development Innovations, LLC
Bayer

Completed

Community Oncology Setting Disease Outcomes of Sorafenib (Nexavar) Use in Advanced Renal Cell Carcinoma

Renal Cell Carcinoma

United States
SCRI Development Innovations, LLC
Novartis

Terminated

LBH589 and Gemcitabine in the Treatment of Solid Tumors

Solid Tumors

United States
SCRI Development Innovations, LLC
Novartis

Completed

Imatinib and PTK787/ZK222584 in Refractory and/or Advanced Solid Tumors

Solid Tumors | Refractory Malignancy

United States
SCRI Development Innovations, LLC
GlaxoSmithKline

Completed

Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage Small-Cell Lung Cancer

Small Cell Lung Cancer | Carcinoma, Small Cell

United States
SCRI Development Innovations, LLC
GlaxoSmithKline

Completed

Weekly Topotecan in Combination With Carboplatin in Two Different Schedules for Refractory and/or Advanced Solid Tumors

Cancer

United States
SCRI Development Innovations, LLC
AstraZeneca

Completed

Iressa in Poor Performance Status Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer

Lung Cancer
SCRI Development Innovations, LLC
Biogen

Completed

Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma

Non-Hodgkins Lymphoma

Clinical Trials Sponsored by ECRI bv

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malta

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations